Yes, sometimes. The only way to cure pancreatic cancer is to remove the tumour completely with surgery; this is possible when the cancer has not yet reached the large blood vessels nearby or distant parts of the body [1, 3]. In the United States, more than 4 in 10 people whose cancer is only in the pancreas are alive 5 years later [1]. Most people are diagnosed when the cancer has already grown and can no longer be cured; but chemotherapy, new medicines and treatment of symptoms help people live longer and more comfortably [1, 11, 12].
Key points
- Surgery with chemotherapy is the only way to cure it; but fewer than 2 in 10 people are diagnosed while the tumour can still be removed with surgery [4].
- In a large study, more than 4 in 10 people who had 6 months of multi-drug chemotherapy after surgery were alive 5 years later [6].
- If the tumour touches large blood vessels to a limited extent, chemotherapy before surgery (sometimes with radiotherapy) improves the chance of living a long time [3, 8].
- When the cancer has spread, the aim is to control it; in people who had already had chemotherapy, a new anti-RAS tablet nearly doubled survival compared with chemotherapy [11].
- Palliative care (treating pain, jaundice, eating problems and worries) should start early in the illness, alongside cancer treatment [12].
- Genetic testing is recommended for everyone with the disease [4]; changes in genes such as BRCA1, BRCA2 or PALB2 in the tumour sometimes make it respond better to some chemotherapies [1].
What is pancreatic cancer, and can "malignant pancreatic cancer" be cured?
The pancreas is an organ behind the stomach that makes digestive enzymes and hormones such as insulin. The most common type of pancreatic cancer (adenocarcinoma) starts in the cells of its ducts, and 9 in 10 pancreatic tumours are of this type [4]. Every cancer is a "malignant" tumour, so "malignant pancreatic cancer" simply means pancreatic cancer. Read more: What is the difference between a benign and a malignant tumour? and Pancreatic cancer.
When doctors talk about a cure, they mean getting rid of the disease completely. In pancreatic cancer this is only possible with surgery, and the outlook is best when the whole tumour is removed [1]. The problem is that most pancreatic cancers are found late, when the whole tumour can no longer be removed [1, 2]: about half of people already have cancer that has spread when they are diagnosed, and about 3 in 10 have a tumour that has wrapped around the large blood vessels [4]. Then the aim of treatment is to help people live longer and to ease symptoms [1]. Know the warning signs: What are the symptoms of pancreatic cancer?
A less common type called a pancreatic neuroendocrine tumour behaves differently and is treated differently. The chance of survival with this type is much higher: in the United States, about 7 in 10 people with this type are alive 5 years later [5]. So first ask your doctor which type of cancer you have; it is written in the pathology report.
How curable is pancreatic cancer? The chance of survival by stage
| Stage | What it means | Out of 10 people |
|---|---|---|
| Only in the pancreas | The cancer has not yet spread outside the pancreas | More than 4 |
| Spread nearby | It has reached lymph nodes or nearby tissue | Nearly 2 |
| Spread to distant parts | It has reached distant parts of the body | Fewer than 1 (about 3 in 100) |
| All stages together | Everyone, at any stage | More than 1 |
Compared with people of the same age without cancer; for people diagnosed between 2015 and 2021, before some of the newer treatments. These numbers are averages and cannot predict what will happen to one person [1].
Treatment at each stage and its aim, in plain words
- 1
Resectable (the tumour is not attached to large blood vessels)
Surgery to remove the tumour, followed by about 6 months of chemotherapy; this is the path that can lead to a cure [1, 6]. In a large study of people who were fit enough for intensive treatment, more than 4 in 10 of those who had four-drug chemotherapy after surgery were alive 5 years later [6]. For people who cannot cope with this treatment, a two-drug combination is an option, and it helped people live longer than a single drug [4, 7].
- 2
Borderline (the tumour touches large blood vessels to a limited extent)
Usually chemotherapy first, sometimes with radiotherapy, and then surgery [3]. In a study in the Netherlands of people with resectable and borderline tumours, with chemotherapy and radiotherapy before surgery, about three times as many people were alive 5 years later as with going straight to surgery [8].
- 3
Locally advanced (the tumour has wrapped around large blood vessels but has not spread)
Treatment starts with chemotherapy, sometimes followed by radiotherapy [4]. In some people these treatments make complete surgery possible [3]; so after a few months of treatment, new scans and a surgeon's opinion are needed. How are these groups decided? See: diagnosis and staging of pancreatic cancer.
- 4
Stage 4 pancreatic cancer: can it be treated, and what is the life expectancy?
Pancreatic cancer that has reached distant parts of the body usually cannot be cured; but it can be treated [1, 2]. Combination chemotherapy slows the growth of the cancer and helps people live longer [4, 9]. Results of treatment in large studies:
- Four-drug chemotherapy (FOLFIRINOX): in people who were in good general health, half lived for nearly a year or longer; longer than people who had a single drug. Fewer people also had a drop in their quality of life [9]. Read more: the FOLFIRINOX regimen.
- Other combinations: gemcitabine with nab-paclitaxel is also a common combination [2]. In a large study, the newer NALIRIFOX regimen helped people live slightly longer than gemcitabine with nab-paclitaxel [10].
- A new anti-RAS tablet (daraxonrasib): in people whose cancer had spread and who had already been treated, half lived for more than a year; nearly twice as long as people who had chemotherapy. Fewer people also stopped treatment because of side effects [11]. Read more: daraxonrasib in pancreatic cancer.
These numbers are study averages; some people live for less time and some for much longer. General health, response to treatment and genetic changes in the tumour all affect the outcome [1]. Read more: Stage 4 cancer: what it means and whether it can be treated
Palliative care means treating pain, weight loss, worry and other symptoms, alongside cancer treatment [2]. The American Society of Clinical Oncology recommends that everyone with advanced cancer receives specialist palliative care early in the illness, at the same time as cancer treatment [12]. If you have jaundice or food cannot pass out of the stomach, a small tube (stent) placed in the bile duct or bowel by endoscopy helps [2]. Read: What is palliative care, and how is it different from hospice?, Cancer pain: it can be treated, do not put up with it and supportive care in pancreatic cancer.
What can I expect after a Whipple operation? Life expectancy after surgery
The Whipple operation is the main surgery for tumours in the head of the pancreas. It removes the head of the pancreas, the gallbladder, part of the small intestine, part of the bile duct and part of the stomach [2]. Enough of the pancreas is left to make digestive enzymes and insulin, but you may need to take enzyme capsules with your meals [2]. Tumours in the body and tail of the pancreas need a different operation, which sometimes removes the spleen as well [2].
This is major surgery, and the best results are achieved by surgeons who do more than 20 Whipple operations a year in an experienced centre [4]. After recovery from surgery, chemotherapy usually starts within 3 months and lasts about 6 months [6, 7].
Life expectancy after a Whipple operation: in a large study of people who had four-drug chemotherapy after surgery, half lived for more than 4 years and more than 4 in 10 were alive 5 years later. These people were under 80 and fit enough for this treatment [6]. But even after successful surgery, the cancer comes back in many people: in the same study, about 1 in 4 people were alive with no sign of the cancer returning 5 years later [6]. This is why regular follow-up is needed. Read: What is cancer recurrence and how is it followed up?
What improves the chance of successful treatment?
Surgery in an experienced centre
Genetic testing
Testing for inherited gene changes is recommended for everyone with pancreatic cancer [4]. If the tumour has a change in genes such as BRCA1, BRCA2 or PALB2, it sometimes responds better to some chemotherapies [1]. Read: Is cancer hereditary?
Complete treatment and keeping your weight up
General health and the ability to cope with treatment affect the outcome, and a lot of weight loss is not a good sign [1]. Complete your course of chemotherapy and tell your doctor about side effects early. If you have had surgery, ask whether you need to take digestive enzyme capsules with your meals to help your nutrition [2]. Read: Nutrition during cancer treatment.
Taking part in clinical trials
Many experts believe that everyone with pancreatic cancer, even at an early stage, should take part in a clinical trial if they can [2]. Ask your doctor whether there is a suitable trial for you.
Frequently asked questions
What is the life expectancy with pancreatic cancer? What is the survival rate?
It depends on the stage, the type of cancer, general health and the response to treatment [1]. In the United States, more than 4 in 10 people whose cancer was only in the pancreas were alive 5 years later; when the cancer had reached distant organs, about 3 in 100 [1]. When the cancer has spread, half of people having the strongest chemotherapy combinations lived for nearly a year or longer [9, 10]. These numbers come from people treated in past years and cannot predict what will happen to one person. Read more: What do cancer survival rates and life expectancy really mean?
If the tumour cannot be operated on, does that mean nothing more can be done?
No. In tumours that have wrapped around blood vessels, chemotherapy (sometimes with radiotherapy) controls the disease and in some people makes surgery possible [3, 4]. When the cancer has spread, chemotherapy and new medicines also help people live longer [9, 11], and palliative care eases symptoms [12].
Is chemotherapy worth it in advanced pancreatic cancer, or does it only make you feel worse?
In a large study, four-drug chemotherapy, compared with a single drug, both helped people live longer and better protected their quality of life: after 6 months, fewer people had a drop in quality of life, even though it had more side effects [9]. The other common combination is gemcitabine with nab-paclitaxel, and your doctor will help you choose the treatment that best fits your circumstances [2]. Make the decision with your doctor, taking your own wishes into account.
Does the new anti-RAS tablet cure pancreatic cancer?
No. In people whose cancer had spread and who had already had chemotherapy, daraxonrasib nearly doubled survival compared with chemotherapy; but its aim is longer control of the disease, not getting rid of it completely [11]. Read more: Daraxonrasib: the first anti-RAS drug
Does pancreatic cancer come back after surgery?
In many people, yes, because small groups of cancer cells that cannot be seen on scans may have been left behind [4]. Chemotherapy after surgery is given to delay the return of the cancer: in a large study, with four-drug chemotherapy the cancer came back later than with a single drug, and about 1 in 4 people were alive with no return of the cancer 5 years later [6]. Regular follow-up and telling your doctor about new symptoms are important.
What does a high CA 19-9 mean in pancreatic cancer?
High blood levels of the tumour markers CA 19-9 and CEA at diagnosis can be a sign of a poorer outlook [1], but this test alone cannot show what will happen to one person. Read more: What does a high CA 19-9 mean?
How curable are other cancers?
The chance of cure differs from one cancer to another. Read: Can cancer be cured?, Is ovarian cancer curable? and Is lung cancer curable?
Survival evidence by stage and treatment (for doctors)
For physicians
Population survival. 5-year relative survival in SEER (diagnosed 2015 to 2021): all stages 13%, localised 44%, regional 17% and distant 3% [1]. The rise from 4% in the mid-1990s to 13% is partly due to more incidentally detected, well-differentiated neuroendocrine tumours (from 4% to 10% of cases), which have 72% survival, compared with 8% for ductal adenocarcinoma [5]. At diagnosis, about 50% of patients have metastatic disease, 10% to 15% resectable disease and 30% to 35% locally advanced disease [4].
Resectable disease. PRODIGE 24/CCTG PA.6 (493 patients aged 18 to 79, 3 to 12 weeks after R0/R1 resection; mFOLFIRINOX vs gemcitabine for 24 weeks): at a median follow-up of 69.7 months, median DFS 21.4 vs 12.8 months (HR 0.66), 5-year DFS 26.1% vs 19.0%, median OS 53.5 vs 35.5 months (HR 0.68; 95% CI 0.54 to 0.85) and 5-year OS 43.2% vs 31.4%; treatment at a high-volume centre was a favourable prognostic factor [6]. ESPAC-4 (730 patients): gemcitabine plus capecitabine vs gemcitabine alone, median OS 28.0 vs 25.5 months (HR 0.82; P=0.032) [7]. In a national cohort of more than 7000 patients (1992 to 1995), in-hospital mortality after pancreaticoduodenectomy was 16% in low-volume hospitals (fewer than 1 procedure a year) vs 4% in high-volume hospitals (more than 5 a year) [3].
Resectable and borderline resectable disease. PREOPANC (246 patients; three cycles of gemcitabine with 36 Gy in 15 fractions, then surgery and 4 cycles of gemcitabine, vs upfront surgery and 6 cycles of gemcitabine): at a median follow-up of 59 months, HR 0.73 (0.56 to 0.96); median OS 15.7 vs 14.3 months but 5-year OS 20.5% vs 6.5%, with a consistent effect in the resectable and borderline subgroups [8]. Neoadjuvant therapy for borderline resectable disease is recommended by several consensus guidelines, and in locally advanced disease the combination of chemotherapy and chemoradiotherapy sometimes makes radical resection possible [3].
Metastatic disease. ACCORD 11 (342 patients, ECOG 0 or 1): median OS 11.1 months with FOLFIRINOX vs 6.8 months with gemcitabine (HR 0.57); objective response 31.6% vs 9.4%; febrile neutropenia 5.4%; definitive deterioration of quality of life at 6 months 31% vs 66% [9]. NAPOLI-3 (770 patients): median OS 11.1 months with NALIRIFOX vs 9.2 months with nab-paclitaxel plus gemcitabine (HR 0.83; 0.70 to 0.99); grade 3 or higher adverse events 87% vs 86% [10]. RASolute 302 (500 previously treated patients; 91.8% with RAS G12 mutations): in the overall population, median OS 13.2 months with daraxonrasib vs 6.7 months with investigator's-choice chemotherapy (HR 0.40) and median PFS 7.2 vs 3.6 months (HR 0.49); grade 3 or higher adverse events 61.8% vs 69.6% and treatment-related discontinuation 1.2% vs 11.2% [11]. ASCO guideline: inpatients and outpatients with advanced cancer should receive dedicated palliative care services early in the disease course, concurrent with active treatment, and referral to interdisciplinary palliative care teams is optimal [12]. Regimens and doses: FOLFIRINOX and mFOLFIRINOX, gemcitabine with nab-paclitaxel and pancreatic cancer treatment regimens.
Scientific evidence
Scientific evidence
6 itemsFive-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial
Related cancer types
Related questions
References
12 referencesShow all references, 7 with a study cardClose the reference list
Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.
- 1
- 2
- 3
- 4
- 5Cancer statistics, 2026
- 6
- 7
- 8
- 9
- 10
- 11
- 12
This page is based on reputable scientific sources and was last updated on 28 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.
Printed from the website; the full and up-to-date version: https://drdabiri.com/en/questions/is-pancreatic-cancer-curable/